000144169 001__ 144169
000144169 005__ 20240229112619.0
000144169 0247_ $$2doi$$a10.1158/1078-0432.CCR-18-1294
000144169 0247_ $$2pmid$$apmid:30850359
000144169 0247_ $$2ISSN$$a1078-0432
000144169 0247_ $$2ISSN$$a1557-3265
000144169 0247_ $$2altmetric$$aaltmetric:56739032
000144169 037__ $$aDKFZ-2019-01718
000144169 041__ $$aeng
000144169 082__ $$a610
000144169 1001_ $$aSjöberg, Elin$$b0
000144169 245__ $$aA Novel ACKR2-Dependent Role of Fibroblast-Derived CXCL14 in Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer.
000144169 260__ $$aPhiladelphia, Pa. [u.a.]$$bAACR$$c2019
000144169 3367_ $$2DRIVER$$aarticle
000144169 3367_ $$2DataCite$$aOutput Types/Journal article
000144169 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1562231718_5866
000144169 3367_ $$2BibTeX$$aARTICLE
000144169 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144169 3367_ $$00$$2EndNote$$aJournal Article
000144169 520__ $$aFibroblasts expressing the orphan chemokine CXCL14 have been previously shown to associate with poor breast cancer prognosis and promote cancer growth. This study explores the mechanism underlying the poor survival associations of stromal CXCL14.Tumor cell epithelial-to-mesenchymal transition (EMT), invasion, and metastasis were studied in in vitro and in vivo models together with fibroblasts overexpressing CXCL14. An approach for CXCL14 receptor identification included loss-of-function studies followed by molecular and functional endpoints. The clinical relevance was further explored in publicly available gene expression datasets.CXCL14 fibroblasts stimulated breast cancer EMT, migration, and invasion in breast cancer cells and in a xenograft model. Furthermore, tumor cells primed by CXCL14 fibroblasts displayed enhanced lung colonization after tail-vein injection. By loss-of function experiments, the atypical G-protein-coupled receptor ACKR2 was identified to mediate CXCL14-stimulated responses. Downregulation of ACKR2, or CXCL14-induced NOS1, attenuated the pro-EMT and migratory capacity. CXCL14/ACKR2 expression correlated with EMT and survival in gene expression datasets.Collectively, the findings imply an autocrine fibroblast CXCL14/ACKR2 pathway as a clinically relevant stimulator of EMT, tumor cell invasion, and metastasis. The study also identifies ACKR2 as a novel mediator for CXCL14 function and thereby defines a pathway with drug target potential.See related commentary by Zhang et al., p. 3476.
000144169 536__ $$0G:(DE-HGF)POF3-311$$a311 - Signalling pathways, cell and tumor biology (POF3-311)$$cPOF3-311$$fPOF III$$x0
000144169 588__ $$aDataset connected to CrossRef, PubMed,
000144169 650_7 $$2NLM Chemicals$$aCXCL14 protein, human
000144169 650_7 $$2NLM Chemicals$$aChemokines, CXC
000144169 7001_ $$aMeyrath, Max$$b1
000144169 7001_ $$0P:(DE-He78)f003032f4174166182cbb6e9e00e7839$$aMilde, Laura$$b2$$udkfz
000144169 7001_ $$aHerrera, Mercedes$$b3
000144169 7001_ $$00000-0002-9339-8059$$aLövrot, John$$b4
000144169 7001_ $$00000-0001-7270-0776$$aHägerstrand, Daniel$$b5
000144169 7001_ $$aFrings, Oliver$$b6
000144169 7001_ $$aBartish, Margarita$$b7
000144169 7001_ $$aRolny, Charlotte$$b8
000144169 7001_ $$aSonnhammer, Erik$$b9
000144169 7001_ $$aChevigné, Andy$$b10
000144169 7001_ $$aAugsten, Martin$$b11
000144169 7001_ $$aÖstman, Arne$$b12
000144169 773__ $$0PERI:(DE-600)2036787-9$$a10.1158/1078-0432.CCR-18-1294$$gVol. 25, no. 12, p. 3702 - 3717$$n12$$p3702 - 3717$$tClinical cancer research$$v25$$x1557-3265$$y2019
000144169 909CO $$ooai:inrepo02.dkfz.de:144169$$pVDB
000144169 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f003032f4174166182cbb6e9e00e7839$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000144169 9131_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000144169 9141_ $$y2019
000144169 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN CANCER RES : 2017
000144169 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144169 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144169 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144169 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144169 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000144169 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144169 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144169 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000144169 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000144169 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bCLIN CANCER RES : 2017
000144169 9201_ $$0I:(DE-He78)A190-20160331$$kA190$$lVaskuläre Onkologie und Metastasierung$$x0
000144169 980__ $$ajournal
000144169 980__ $$aVDB
000144169 980__ $$aI:(DE-He78)A190-20160331
000144169 980__ $$aUNRESTRICTED